Acapodene toremifene: Phase III data

Data from the 2-year, U.S. and Mexican Phase III trial in 913 evaluable men receiving androgen deprivation therapy (ADT) for advanced prostate cancer showed that 80 mg Acapodene toremifene met the pri...